By far the largest, longest, and geographically broadest in history, the 2013-2016 Ebola virus disease (EVD) outbreak in West Africa provided a sobering look at the severe end of a devastating clinical disease spectrum associated with human Ebola virus (EBOV) infection [1] . As the outbreak ended, epidemiologic investigation of close contacts of known EVD cases detected anti-EBOV antibodies in 12 of 185 (6.5%) [2] and 10 of 388 (2.6%) [3] of Sierra Leonean close household contacts who either did not have or did not recognize, report, or recall symptoms of EVD. Unsurprisingly, this has piqued interest in questions at the opposite end of the human-EBOV interaction. To put it simply, does EBOV infection always equal EBOV disease? and what do these serologic footprints mean?
These are not new questions, either of outbreak settings or areas not known to be previously affected by EVD. Indeed, they revisits founding events: immunofluorescent antibody (IFA)-positive individuals without obvious clinical disease were first identified in 1976 after coincident but unrelated EBOV and Sudan virus outbreaks in present Democratic Republic of the Congo (DRC) and Sudan, respectively [4] [5] [6] [7] . In the 40 years since then, an underappreciated large set of serosurveys have been completed, retrospectively dating back to 1961. These data have been comprehensively compiled [8] , although distilling meaningful comparisons is made almost impossible by wide variability in (1) study population size, setting, and exposure, (2) the use or nonuse of appropriate control groups, (3) the selection of particular antibody detection assays (IFA vs enzyme linked immunosorbent assay [ELISA] vs Western blot), and (4) particular intra-assay parameters (whole virus vs recombinant antigens, selection of appropriate cutoffs) [9] . Dusting off and updating this large dataset, Bower and Glynn [10] recently systematically reviewed studies reporting EBOV serology from >80 sample populations (>40 000 individuals from >20 countries) that either reported no symptoms during or after an EVD outbreak or were from settings with no known prior outbreaks and were, therefore, assumed to be asymptomatic.
Closer examination of historical close contacts of known EVD cases illustrates the difficulty in making sense of seroprevalence results. In their meta-analysis of 8 comparable close-contact studies (including the Sierra Leonean studies above), 3.3% (95% confidence interval [CI], 2.4-4.4) of asymptomatic close contacts from known EVD cases were anti-EBOV antibody positive [10] . This is in contrast to an estimated 27% (albeit with much greater heterogeneity; 95% CI, 14.5-39.6) of asymptomatic close contacts from another meta-analysis drawn from studies that enabled determination of household transmission and secondary attack rate [11] . Even more difficult to interpret are results in individuals "without close contact" from prior EVD outbreak settings or "from non-outbreak settings", where seroprevalence ranges widely (0%-29%) in data mainly from small cohorts [10] . In general, these data have not clarified uncertainty around wide historical heterogeneity in EBOV seroprevalence from both outbreak and non-outbreak settings in Africa nor their influence on epidemic potential [12] .
Even if that heterogeneity could be put aside and an accurate EBOV seroprevalence landscape described, understanding its determinants is difficult, and size matters: studies large enough to power population-wide estimates and analysis of contributing risk factors are even more limited. In randomly surveyed villages in Gabon (an area with known prior outbreaks), 667 of 4349 (15.3%) individuals were anti-EBOV antibody positive; this was highest in forested versus other ecosystems but was not associated with particular demographic, exposure, or human activity [13] . In an area of the Central African Republic (with no known outbreaks), 335 of 4078 (8.2%) individuals were seropositive, with no associated risk factors identified [14] .
Perhaps nowhere is uncertainty about this immunologic footprint more relevant than in the DRC, which has experienced 8 documented outbreaks of EBOV alone since 1976, typically in remote, rural, and forested areas that make disease surveillance and outbreak detection and management challenging [15, 16] . Limited serological surveys have shown variable seropositivity in 1.1% and 9.3% of individuals living in unaffected villages near previous outbreak sites of Yambuku (1976) [5] and Kikwit (1995) [17] , respectively. In a non-outbreak setting in north-eastern DRC, 18 .7% of Efe Pygmies tested in 2002 were seropositive; this was associated with increasing age but not with expected environmental or ecological exposures [18] .
In this issue of The Journal of Infectious Diseases, Mulangu et al report results of the largest population-based serosurvey completed in the DRC to date. From August to September 2007, they determined anti-EBOV immunoglobulin (Ig)G antibody status in healthy individuals from rural villages randomly selected from 2 health zones in the Sankuru district (Kasai Orientale Province). Although these were considered non-outbreak settings, the health zones were proximate in time and space to the 2007 Mweka/Luebo EBOV outbreak, in which a potential epidemiologic link to fruit bats has been speculated [19] . Sera were assayed with ELISA to recombinant EBOV-nucleoprotein, compared with a Kinshasa control group presumed geographically to be unexposed, and associations of seropositivity with socio-demographic factors were determined. Of >3000 individuals, 11% were EBOV-nucleoprotein antibody-positive overall. Notable socio-demographic factors independently associated with antibody detection included age >15 years, male sex, and health zone: residents from Kole had a significantly higher rate of seropositivity versus Lomela (12% vs 8%; P = .0003; adjusted odds ratio [aOR], 1.58; 95% CI, 1.22-2.04). A total of 2580 (75%) individuals in the study population completed a detailed assessment of potential at-risk behavioral activities as well as yes/no asks of specific exposure to animal species or groups over the prior month. Multivariate analysis (controlled for age, sex, and health zone) found an increased OR of seropositivity in individuals who had entered the forest regularly (aOR, 1.75; 95% CI, 1.00-3.05) or had any exposure to rodents (aOR, 1.77; 95% CI, 1.02-3.04), with trends observed among those who hunted or were exposed to duikers. There were no associations with exposure to nonhuman primates or bats.
This large study fills relevant gaps in the EBOV seroprevalence map in a non-outbreak setting in the DRC, confirming in large numbers that individuals outside areas previously affected by EVD outbreaks have significant rates of detectable anti-EBOV antibody. Associations of seropositivity and older age confirm that seen earlier in smaller number of Efe Pygmies [18] , whereas the association with male sex is newly described here. Regarding location, the Kole health zone had a significantly higher frequency of seropositivity; it was also closest in proximity to the 2007 Mweka/Luebo outbreak site. Some caution in interpretation is needed: there was no linear relationship with proximity to Mweka (indeed, this study was not designed to detect any geographical gradient), and care must be taken not to relate between-health zone differences in seroprevalence to proximity to Mweka/Luebo nor to make conclusions about differences among particular villages in each health zone. Finally, this study is the first large population survey to identify particular human behavioral (frequent forest visits) or specific animal risk factors (exposure to rodents) for human EBOV seropositivity. In light of how little we know about a yet-to-be identified reservoir host and its potential interactions with humans or other animals, these associations, even if proxies for another driver, are hypothesis-generating and important fodder for further study.
Put in more recent context, this study's 11% overall antibody prevalence provokes more questions. The 2014 Boende EBOV outbreak provided a 4 and 2 decade fast-forward from Yambuku (1976) and Kikwit (1995) . In a much smaller serologic survey around that outbreak, EBOV IgG antibody was detected in only 1.4% of asymptomatic residents of households where at least 1 EVD case was detected, and this prevalence was not different in residents of households from an unaffected area. In fact, the only association found was between antibody titer and increasing age [20] . Zooming in to this specific terrain, past or present, fails to reconcile the serologic incongruity.
Potential explanations for heterogeneity in EBOV serology results have been thoughtfully posited [9] . They include, but are not limited to, several possible "truths" underlying the detection of anti-EBOV antibody in an asymptomatic individual: first, an unknown antibody in African sera is cross-reacting to EBOV antigens, ie, this is an artifactual footprint that does not reflect EBOV infection; second, detectable antibody results from human interaction with an undiscovered non-pathogenic or mildly pathogenic filovirus, ie, this is a footprint of a close but unknown cousin; third, asymptomatic human EBOV infection is a common, underappreciated result of a human-EBOV interaction, leaving an antibody footprint of an EBOV infection that does not always equal EBOV disease. Regarding the last possibility, a few intrinsic assumptions not often discussed require unpacking. Retrospectively classifying an infection as truly asymptomatic is difficult for patient, clinician, and researcher. In addition to obvious recall and timing bias, obtaining accurate clinical disease histories is challenging, especially in large studies, and differential stoicism towards illness in different patient populations makes assignation as "asymptomatic" or even "minimally symptomatic" challenging. Perhaps not as obvious, the host-pathogen determinants of this side of a disease spectrum are unknown and may involve exposure to EBOV antigen alone rather than infection with viable EBOV.
The recent and eighth EBOV outbreak in the DRC (Likati, May, 2017) [21] highlighted the ongoing need to further understand these long-described but poorly understood phenomena at both the individual host-pathogen and population/ecological levels. This largest population survey to date confirms and further defines a large EBOV antibody serologic footprint in a non-outbreak setting in the DRC, begging the question, again: who goes there? 
